MedPath

Prospective study of switch to 3TC monotherapy with evaluation of replication capacity in patients with virologic failure and 3TC resistance (a multicenter prospective clinical study within the SHCS) SHCS-Projekt Nr. 408 - 3TC Mono Study

Conditions
HIV patients with virological treatment failure due to multi-drug-resistant virus including 3TC resistance
Registration Number
EUCTR2004-002633-39-DE
Lead Sponsor
Prof. Dr. med. Milos Opravil, Universitätsspital Zürich
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
30
Inclusion Criteria

Documented HIV-1 infection with clade B virus.
•Patients undergoing resistance testing because of virologic failure, defined as two consecutive HIV RNA values >400 copies/ml with the second one >1000 copies/ml.
•Currently on (for at least 3 months) stable HAART (3 or more antiretroviral drugs).
•CD4 >300/µl and no active opportunistic infection.
•HIV RNA 1000 – 100'000 copies/ml.
•Presence of the 184V or 184I RT mutation, or 3TC phenotypic resistance.
•Additional resistance, defined as either genotypic mutations to at least one additional major NRTI (K65R; 69 insertion; T69D,N; L74I,V; V75A,T; Q151L,M; T215F,Y) and at least one major PI (D30N; G48V; I50N; V82A,F,S,T; I84V,A; L90M) mutation; or as a phenotypic resistance to at least one additional NRTI and one protease inhibitor.
•Written informed consent.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Prior documented intolerance of 3TC.
•Patients participating in other clinical trials.
•Patients receiving immunomodulators or undergoing structured treatment interruptions.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath